BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market

Rhea-AI Summary

BMO is set to host its second annual Obesity Summit on March 25, 2025, in New York, focusing on the expanding $150 billion obesity therapies market. The summit will bring together healthcare industry experts and leaders to examine trends in metabolic disease and drug therapies.

The event features prominent companies including Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock, and Structure Therapeutics. Participants will explore advances in GLP-1 drug therapies with insights from pharmacy benefit managers, patients, and providers.

The summit's agenda includes fireside chats, expert panels, and presentations featuring BMO Sr. Biotechnology & Pharmaceuticals Analyst Evan Seigerman, FlyteHealth Co-Founder Dr. Katherine Saunders, and Dr. Louis J. Aronne, Sanford I. Weill Professor of Metabolic Research. Key topics include care delivery, emerging technologies, coverage and access, and patient insights on GLP-1+ therapy.

Positive

• BMO positioning itself as a thought leader in the rapidly growing $150 billion obesity therapies market
• High-profile participation from major pharmaceutical companies indicates strong industry engagement

Negative

• None.

Healthcare industry experts and leaders to convene March 25 at the 2025 BMO Obesity Summit to examine outlook and trends in metabolic disease and drug therapies

NEW YORK, March 18, 2025 /PRNewswire/ - Join BMO and industry leaders in New York on March 25 for the BMO 2025 Obesity Summit to discuss the growing $150 billion obesity therapies market. The Summit features an exciting line-up of leaders in the space as well as next generation players from Altimmune, Amgen, Corbus Pharmaceuticals and Eli Lilly, to FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock and Structure Therapeutics. Participants will focus on the advances in GLP-1 drug therapies and feature expert insights from pharmacy benefit managers, patients, and providers to help identify and discuss the opportunities and challenges in this market.

What:	2025 BMO Obesity Summit
When:	Tuesday, March 25, 2025
Where:	Convene, 360 Madison Ave, New York
Media:	Register here

The BMO Obesity Summit will deliver thought leadership and corporate management perspectives in a variety of formats such as fireside chats, expert panels and presentations, including:

• Discussions with leading life sciences companies hosted by BMO analysts, including Sr. Biotechnology & Pharmaceuticals Analyst, Evan Seigerman
• Obesity 102 with Katherine Saunders, MD, Obesity Physician & Co-Founder, FlyteHealth
• A discussion with Dr. Louis J. Aronne, M.D., Sanford I. Weill Professor of Metabolic Research
• Panels on care delivery, emerging technologies, coverage and access
• Insights from patients on GLP-1+ therapy

For more information or to request an interview with one of BMO's equity research analysts, please contact BMO Media Relations using the contact details below. Note: There may be restrictions for media on access to some presentations.

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of January 31, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.

 

SOURCE BMO Financial Group

FAQ

When and where is BMO's 2025 Obesity Summit taking place?

The BMO Obesity Summit is scheduled for March 25, 2025, in New York.

What is the current size of the obesity therapies market discussed at the BMO Summit?

The obesity therapies market is valued at $150 billion.

Which major pharmaceutical companies are participating in BMO's 2025 Obesity Summit?

Key participants include Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, Novo Nordisk, and others.

What are the main topics being discussed at the 2025 BMO Obesity Summit?

The summit focuses on GLP-1 drug therapies, care delivery, emerging technologies, coverage and access, and patient insights.